United States Federal Circuit

In this patent litigation involving U.S. Patent No. 7,101,576 (Patent 576), which claims methods of using nanosized formulations of the drug megestrol acetate to increase body mass in sufferers of anorexia, cachexia, or wasting, judgment finding the asserted claims of Patent 576 invalid as obvious is vacated and remanded for further analysis, where the district court incorrectly applied inherency law in the context of obviousness.

Appellate Information

• Decided 12/03/2014
• Published 12/03/2014

Judges

• O'Malley

Court

• United States Federal Circuit

Counsel